Skip to main content
Fig. 1 | BMC Pulmonary Medicine

Fig. 1

From: A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Fig. 1

Planned dose-escalation scheme and treatment allocation (active:placebo). Because of a high proportion of ADAs in healthy volunteers, only one subject with atopic asthma was enrolled in Cohort I before study termination. HV, healthy volunteers; Q4W, every four weeks

Back to article page